BCAX Heads Into Earnings With High Short Interest and an Activist on the Register

Bicara Therapeutics enters its November 10 earnings date carrying one of the heavier short burdens in clinical-stage biotech, an on-register activist, and a Street consensus that sits well above where the stock is trading today.

The most striking feature of the positioning picture is that short interest, at 19.1% of the free float, has been broadly stable for six weeks rather than building or collapsing. The level is elevated by any measure, roughly 10.5 million shares on loan, and FINRA's most recent official fortnightly figure of 10.3 million shares confirms the estimate. Yet the borrow market itself tells a calmer story. Availability is generous at 385%, meaning there are roughly four shares still available to borrow for every one already out on loan. That compares with a 52-week low availability of around 100%, so the pool is nowhere near stretched. Cost to borrow has also eased sharply, down a third over both the past week and the past month to just 0.32%, its lowest level in the 30-day window. Shorts are not scrambling to maintain positions. The ORTEX short score of 72, which has barely moved over the past two weeks, reflects a stock that is heavily positioned against but not at a tipping point. Options add a mild defensive tilt: the put/call ratio is at 0.83, a little above its 20-day average of 0.80, roughly 1.4 standard deviations higher, though well within the range of normal market noise given the year's PCR high of 26.5.

The Street is significantly more constructive than the current price implies. The mean analyst price target is $35.67, more than double where BCAX closed at $17.48 on Tuesday. The most recent action came from BTIG on October 19, reiterating Buy with a $39 target. Back in August, following the company's last data readout, the analyst community broadly lifted targets: Morgan Stanley raised to $39, BTIG to $39, Wedbush to $33, while Goldman Sachs and Mizuho moved to $20 on Neutral ratings and Wells Fargo went to $23 at Equal-Weight. The bull case centres on ficerafusp alfa's clinical differentiation, specifically a 25% complete response rate and an estimated 31% three-year overall survival rate in first-line HPV-negative head-and-neck squamous cell carcinoma, alongside a $497 million cash runway extending into the first half of 2029. The bear case is competitive: petosemtamab has a first-mover advantage in the same indication, and amivantamab is also showing activity. Even successful development leaves Bicara facing a crowded commercial landscape. The factor scorecard reflects this tension: EPS momentum over 30 days scores in the 66th percentile, but the 12-month forward EPS year-on-year trajectory ranks in just the 3rd percentile, and the short score factor sits in the 9th percentile.

One ownership detail adds a meaningful layer to this setup. RA Capital Management filed a Schedule 13D in March 2026, disclosing an 11.5% stake of 7.3 million shares. A 13D filing signals active rather than passive intent, and RA Capital's presence on the register is one of the more newsworthy facts about this stock. Separately, T. Rowe Price added 304,000 shares in the quarter to September 30, BlackRock added just over a million shares in the same period, and State Street and Vanguard both added material positions. The institutional build is real, albeit partly offset by T. Rowe Price Investment Management cutting its disclosed stake from 10.1% to 4.2% across three filings, the last on October 7. FMR similarly trimmed from 6.1% to 3.2%. Insider activity across August and September was entirely under pre-arranged 10b5-1 plans, option exercises followed by same-day sales at prices in the $23 to $28 range. These are compensation mechanics rather than conviction signals, and should be read as such.

The earnings history is thin but pointed. The most recent print, in August 2026, produced an 11.2% one-day decline and a further move of minus 10.1% over the following five days. The prior event generated a fractional one-day dip but then recovered nearly 9% across the week. The sample is too small to draw reliable conclusions, but the asymmetry of the August reaction, a sharp fall in both timeframes, is worth carrying into the November 10 date. Peers finished the week mixed: OLMA fell 2.9% while MGTX dropped 5.7%, compared with BCAX's own 4.7% weekly decline.

With 13 days to the next data event, the question is whether the high short interest stays anchored or begins to move in response to any clinical or regulatory newsflow ahead of the print, and whether the Street's substantial premium to the current price gets any further validation from the company's HNSCC data timeline.